Newco Solvanix's technology can reduce the aggregation of mAbs by introducing as few as two mutations, without affecting binding or immunogenicity.
Cardiologist Philip Sager says the current thinking on preclinical cardiovascular safety involves new ways of looking at ion conductance to replace QT, and might enable or rescue many compounds.
NIH's meeting with G7 health leaders coincided with three announcements about AD funding, and stakeholders are optimistic the field is starting to get some much-needed attention.
A T cell-based fingerprint in the plasma of kidney transplant recipients could identify patients who will develop tolerance and not need immunosuppressive therapy.
THE DISTILLERY brings you this week's most essential scientific findings in therapeutics, distilled by Innovations editors from a weekly review of more than 400 papers in 41 of the highest-impact journals in the fields of biotechnology, the life sciences and chemistry. The Distillery goes beyond the abstracts to explain the commercial relevance of featured research, including licensing status and companies working in the field, where applicable.
This week in therapeutics includes important research findings on targets and compounds, grouped first by disease class and then alphabetically by indication.
This week in techniques includes findings about research tools, disease models and manufacturing processes that have the potential to enable or improve all stages of drug discovery and development.